@article{a44451dcd8f6426a868d1b5f7f4a0b33,
title = "Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles",
abstract = "Nanoparticles offer new options for medical diagnosis and therapeutics with their capacity to specifically target cells and tissues with imaging agents and/or drug payloads. The unique physical aspects of nanoparticles present new challenges for this promising technology. Studies indicate that nanoparticles often elicit moderate to severe complement activation. Using human in vitro assays that corroborated the mouse in vivo results we previously presented mechanistic studies that define the pathway and key components involved in modulating complement interactions with several gadolinium-functionalized perfluorocarbon nanoparticles (PFOB). Here we employ a modified in vitro hemolysis-based assay developed in conjunction with the mouse in vivo model to broaden our analysis to include PFOBs of varying size, charge and surface chemistry and examine the variations in nanoparticle-mediated complement activity between individuals. This approach may provide the tools for an in-depth structure-activity relationship study that will guide the eventual development of biocompatible nanoparticles.",
keywords = "Complement, Hemolysis Assay, Mouse Model, Nanomedicine, Nanoparticles, Perfluorocarbon",
author = "Pham, {Christine T.N.} and Thomas, {Dennis G.} and Julia Beiser and Mitchell, {Lynne M.} and Huang, {Jennifer L.} and Angana Senpan and Grace Hu and Mae Gordon and Baker, {Nathan A.} and Dipanjan Pan and Lanza, {Gregory M.} and Hourcade, {Dennis E.}",
note = "Funding Information: The project described was supported primarily by grant number U01NS073457 from the National Institutes of Health (NIH) and The Food and Drug Administration (FDA). Additional grant support from the NIH and Department of Defense (DOD) included: R01AI051436, HL112518, HL113392, CA100623, CA154737, AR056468, CA136398, Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the NIH, and the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness, Inc. Unrestricted grant, and the NIH Vision Core Grant P30 EY 02687. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, DOD or the FDA. C.T.N.P., D.G.T., J.B., L.M.M., J.L.H., A.S., G.H., M.G., N.A.B, and D.E.H. have no commercial interests related to this work. G.M.L.is a co-inventor on a patent licensed by Washington University of St. Louis to Ocean NanoTech (ONT), Inc AR. He has co-invented patented technology licensed by Kereos, Inc from Barnes-Jewish Hospital/Washington University Medical School. He is the co-founder of Kereos, Inc, a nonexecutive CSO, has equity worth less than $5000.00, and receives small royalty payments indirectly through the BJH-Kereos agreement. D.P. is a co-inventor on a patent licensed by Washington University of St. Louis to Ocean NanoTech (ONT), Inc AR. He serves no role, has no equity position, and receives no royalties from ONT. ",
year = "2014",
month = apr,
doi = "10.1016/j.nano.2013.10.012",
language = "English",
volume = "10",
pages = "651--660",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
number = "3",
}